文献速递预防保健、筛查与疫苗慢病管理老年与多病共存

接种疫苗与未接种疫苗的美国退伍军人感染德尔塔和奥密克戎变异株的不良结局:回顾性队列研究

Adverse outcomes of SARS-CoV-2 infection with delta and omicron variants in vaccinated versus unvaccinated US veterans: retrospective cohort study.
PubMed 文献 · BMJ · 2023-05-23

该回顾性队列研究纳入美国退伍军人事务部医疗系统中在德尔塔或奥密克戎变异株流行期首次确诊SARS-CoV-2感染的成人(≥18岁)。德尔塔期95 336例患者中47.6%至少接种一剂疫苗,奥密克戎期184 653例中72.6%接种疫苗。调整人口学和临床特征后,接种两剂mRNA疫苗与未接种相比,在德尔塔期和奥密克戎期均与较低的住院、ICU入住、机械通气和死亡 odds 相关;奥密克戎期第三剂mRNA疫苗较两剂进一步降低所有结局 odds。

要点

  • 德尔塔期两剂mRNA疫苗与未接种相比,住院调整OR 0.41,死亡调整OR 0.21。
  • 奥密克戎期两剂mRNA疫苗与未接种相比,住院调整OR 0.60,死亡调整OR 0.43。
  • 奥密克戎期第三剂mRNA疫苗较两剂进一步降低住院(OR 0.65)和死亡(OR 0.51) odds。

核心结论

  • 在近期有医疗使用且多病共存高发的退伍军人中,接种疫苗与感染新冠后30天发病和死亡 odds 显著降低相关。
  • 疫苗类型和剂次与结局显著相关。

研究设计与样本

  • 回顾性队列研究,设置于美国退伍军人事务部医疗系统。
  • 合并队列平均年龄59.4岁(标准差16.3),87%为男性。

主要发现

  • 德尔塔期95 336例感染,47.6%至少接种一剂疫苗;奥密克戎期184 653例感染,72.6%接种疫苗。
  • 德尔塔期两剂mRNA疫苗与未接种相比,住院调整OR 0.41(95%CI 0.39-0.43),ICU入住0.33(0.31-0.36),机械通气0.27(0.24-0.30),死亡0.21(0.19-0.23)。
  • 奥密克戎期两剂mRNA疫苗与未接种相比,住院调整OR 0.60(0.57-0.63),ICU入住0.57(0.53-0.62),机械通气0.59(0.51-0.67),死亡0.43(0.39-0.48)。
  • 奥密克戎期第三剂mRNA疫苗较两剂相比,住院调整OR 0.65(0.63-0.69),ICU入住0.65(0.59-0.70),机械通气0.70(0.61-0.80),死亡0.51(0.46-0.57)。
  • Ad26.COV2.S疫苗与未接种相比结局更好,但住院和ICU入住 odds 高于两剂mRNA疫苗;BNT162b2总体上结局劣于mRNA-1273(调整OR介于0.97和1.42之间)。

临床怎么用

  • 在德尔塔和奥密克戎变异株流行期,mRNA疫苗两剂接种与感染后30天住院、ICU、通气和死亡 odds 降低相关。
  • 奥密克戎期第三剂mRNA疫苗较两剂进一步降低不良结局 odds。
  • 疫苗类型与结局相关,Ad26.COV2.S 与未接种相比结局更好但劣于两剂mRNA疫苗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the association between covid-19 vaccination types and doses with adverse outcomes of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection during the periods of delta (B.1.617.2) and omicron (B.1.1.529) variant predominance. DESIGN: Retrospective cohort. SETTING: US Veterans Affairs healthcare system. PARTICIPANTS: Adults (≥18 years) who are affiliated to Veterans Affairs with a first documented SARS-CoV-2 infection during the periods of delta (1 July-30 November 2021) or omicron (1 January-30 June 2022) variant predominance. The combined cohorts had a mean age of 59.4 (standard deviation 16.3) and 87% were male. INTERVENTIONS: Covid-19 vaccination with mRNA vaccines (BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna)) and adenovirus vector vaccine (Ad26.COV2.S (Janssen/Johnson & Johnson)). MAIN OUTCOME MEASURES: Stay in hospital, intensive care unit admission, use of ventilation, and mortality measured 30 days after a positive test result for SARS-CoV-2. RESULTS: In the delta period, 95 336 patients had infections with 47.6% having at least one vaccine dose, compared with 184 653 patients in the omicron period, with 72.6% vaccinated. After adjustment for patient demographic and clinical characteristics, in the delta period, two doses of the mRNA vaccines were associated with lower odds of hospital admission (adjusted odds ratio 0.41 (95% confidence interval 0.39 to 0.43)), intensive care unit admission (0.33 (0.31 to 0.36)), ventilation (0.27 (0.24 to 0.30)), and death (0.21 (0.19 to 0.23)), compared with no vaccination. In the omicron period, receipt of two mRNA doses were associated with lower odds of hospital admission (0.60 (0.57 to 0.63)), intensive care unit admission (0.57 (0.53 to 0.62)), ventilation (0.59 (0.51 to 0.67)), and death (0.43 (0.39 to 0.48)). Additionally, a third mRNA dose was associated with lower odds of all outcomes compared with two doses: hospital admission (0.65 (0.63 to 0.69)), intensive care unit admission (0.65 (0.59 to 0.70)), ventilation (0.70 (0.61 to 0.80)), and death (0.51 (0.46 to 0.57)). The Ad26.COV2.S vaccination was associated with better outcomes relative to no vaccination, but higher odds of hospital stay and intensive care unit admission than with two mRNA doses. BNT162b2 was generally associated with worse outcomes than mRNA-1273 (adjusted odds ratios between 0.97 and 1.42). CONCLUSIONS: In veterans with recent healthcare use and high occurrence of multimorbidity, vaccination was robustly associated with lower odds of 30 day morbidity and mortality compared with no vaccination among patients infected with covid-19. The vaccination type and number of doses had a significant association with outcomes.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Bohnert AS, Kumbier K, Rowneki M, et al. Adverse outcomes of SARS-CoV-2 infection with delta and omicron variants in vaccinated versus unvaccinated US veterans: retrospective cohort study. BMJ. 2023. PMID: 37220941. doi:10.1136/bmj-2022-074521

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。